Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California



 

Recent News and Articles on the Keywords: cancer + may + growth  Related to the article below (Last Update: 8/5/2008)


ABC News
Vitamin C stops cancer, slows tumour growth in mice
Xinhua, China -
It may also act as an antioxidant, protecting cells from the damaging effects of free radicals. Vitamin C was considered as a possible treatment for cancer ...
Vitamin C 'slows cancer growth' BBC News
Injected vitamin C cuts cancer growth ABC Online
Vitamin C jabs may combat cancer New Scientist (subscription)
ABC News - SINDH TODAY
all 85 news articles »
Drug combo may improve cancer therapy efficacy
Newstrack India, India - Aug 2, 2008
Further, this drug combination showed enhanced efficacy at stalling tumour growth in an orthotopic mouse model of GBM. The authors revealed that combining ...
YM BIOSCIENCES REPORTS PHASE II DATA FOR NIMOTUZUMAB IN METASTATIC ...
FOXBusiness -
"The results support further development of nimotuzumab in this setting and trials in metastatic colorectal cancer are high on the list of indications that ...YMI - OTC:CMTX
How Tumor Suppress or Inhibits Cell Growth
Newswise (press release) -
The finding may prove to be very important in scientists? search for novel inhibitors that stop or slow cancer tumor growth. In fact, Budanov obtained ...
Turned-off cannabinoid receptor turns on colorectal tumor growth
Hindu, India - Aug 3, 2008
It now may serve as a new path for cancer prevention or treatment. "We've found that CB1 expression is lost in most colorectal cancers, and when that ...
For the men who develop prostate cancer, early testing can improve ...
Orlando Sentinel, FL - 20 minutes ago
Patients with more advanced cancer may undergo hormone therapy or chemotherapy. A growing number of patients are turning to a relatively new technique: ...
German Association of Gynecology and Obstetrics Recommends HPV ...
MarketWatch -
"By using both tests for women 30 and over, when cervical cancer is most common, we hope to greatly reduce the number of women suffering and dying from this ...
Infinity Highlights Clinical Advances in Its Portfolio of Anti ...
MarketWatch -
an innovative cancer drug discovery and development company, today provided a research and development (R&D) update and announced financial results for the ...INFI
Nastech Pharmaceutical Company Inc. Q2 2008 Earnings Call Transcript
Seeking Alpha, NY -
With regard to PLK-1, knock down of this target has been demonstrated to prevent the growth of bladder cancer in a mouse model. ...MRNA
Lifewatch: Skin Cancer
WECT-TV6, NC -
Steve learned that if the cancer had already spread, he may be down to months or a year to live. Now, Steve is trying to get the word out on what to watch ...
Source: Google News

[PDF] Circulating concentrations of insulin-like growth factor-I and risk of breast cancer -
SE Hankinson, WC Willett, GA Colditz, DJ Hunter, … - Lancet, 1998 - mcgill.ca
... breast-cancer prevention, such as retinoids, transforming growth factor-B, and vitamin
D analogues, also upregulate IGFBP expression?an action that may be ...
-

Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the … -
AJ Stewart, MD Johnson, FE May, BR Westley - Journal of Biological Chemistry, 1990 - ASBMB
... Chen and MS Wong Genistein Enhances Insulin-Like Growth Factor Signaling Pathway
in Human Breast Cancer (MCF-7) Cells J. Clin. Endocrinol. Metab., May 1, 2004 ...

Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non-Small Cell Lung Cancer A … -
MG Kris, RB Natale, RS Herbst, TJ Lynch, D Prager, … - JAMA, 2003 - Am Med Assoc
... The pathobiology of growth-factor signaling in lung cancer may be fundamentally
different from that in other tumors, in which blockade of growth-factor ...

… Study of Colorectal Cancer Risk in Men and Plasma Levels of Insulin-Like Growth Factor (IGF)-I and … -
J Ma, MN Pollak, E Giovannucci, JM Chan, Y Tao, CH … - jnci, 1999 - jnci.oxfordjournals.org
... IGF-I may also induce the expression of vascular endothelial growth factor, which
can promote the progression of cancer by regulating the development of new ...

… in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to … -
TJ Lynch, DW Bell, R Sordella, S Gurubhagavatula, … - New England Journal of Medicine, 2004 - content.nejm.org
... Head and Neck Cancers to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
May Be Linked to Mutation of ERBB2 rather than EGFR. Clin Cancer Res 11 ...

Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. -
H Sheng, J Shao, SC Kirkland, P Isakson, RJ Coffey … - Journal of Clinical Investigation, 1997 - pubmedcentral.nih.gov
... Here we provide evidence that there may be a direct link between inhibition of
intestinal cancer growth and selective inhibition of the COX-2 pathway. ...

Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis -
D Shweiki, A Itin, D Soffer, E Keshet - Nature, 1992 - palgrave-journals.com
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated ...
Here we show that vascular endothelial growth factor (VEGF; also ... Cancer Res ...

Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse … -
RS Warren, H Yuan, MR Matli, NA Gillett, N Ferrara - J Clin Invest, 1995 - pubmedcentral.nih.gov
... Cancer Res. 1994 May 15;54(10):2604?2610. [PubMed]; Kelly PA, Djiane J, Postel-Vinay
MC, Edery M. The prolactin/growth hormone receptor family. Endocr Rev. ...

Transforming growth factor alpha may be a physiological regulator of liver regeneration by means of … -
JE Mead, N Fausto - Proceedings of the National Academy of Sciences of the …, 1989 - pubmedcentral.nih.gov
... Inhibition of DNA synthesis in rat hepatocytes by platelet-derived type beta
transforming growth factor. Cancer Res. 1986 May;46(5):2330?2334. ...

Posttraumatic growth following breast cancer: a controlled comparison study. -
MJ Cordova, LL Cunningham, CR Carlson, MA … - Health Psychol, 2001 - ncbi.nlm.nih.gov
Health Psychol. 2001 May;20(3):176-85. Click here to read Posttraumatic growth
following breast cancer: a controlled comparison study. ...

Source: Google Scholar
 

Targeting Sugar on Blood Vessels May Inhibit Cancer Growth

In a study that could point to novel therapies to prevent cancer spread, or metastasis, researchers at the University of California, San Diego (UCSD) School of Medicine have targeted a sugar that supports blood vessel growth in the tumor. Their findings will be published in the May 7 on-line issue of Journal of Cell Biology.

Lung cancer is the most common cause of cancer death and an area where novel therapies to block metastasis are desperately needed, according to first author Mark M. Fuster, M.D., assistant professor in the Division of Pulmonary and Critical Care Medicine in UCSD’s Department of Medicine. Solid tumors need a network of blood vessels, or vasculature, in order to grow, and this vasculature drives metastasis. The research team, led by the paper’s principal investigator Jeffrey D. Esko, Ph.D., professor of Cellular and Molecular Medicine at UCSD, showed that modifying the action of heparan sulfate uniquely impacted the tumor vasculature, and in doing so, altered the growth rate of tumors prepared from lung carcinoma cells in the mice.

Article continues below and (thank you)

 

Altered tumor vasculature in endothial-targeted Ndst1 knockout mice.

“We theorized that by targeting the sugar, heparan sulfate, we could affect angiogenesis, which is the formation of new blood vessels,” said Fuster. “In cancer, angiogenesis sustains growth as well as metastasis of tumors. An important finding was that, not only could we inhibit the growth of tumors in these mice, but that other systems that rely on endothelial growth, such as the reproductive system and wound healing, remained robust.”

Studying mouse models with a genetic alteration in an important sugar-modifying enzyme (Ndst1), the researchers saw a marked decrease in the growth of experimental carcinomas. The Ndst1 enzyme is responsible for modifying the molecular structure of a sugar called heparan sulfate. In endothelial cells, this sugar facilitates the action of several important vascular growth factors that support angiogenesis.

An antibody drug called Avastin, produced by Genentech, has been shown to block a major pro-angiogenesis molecule called vascular endothelial growth factor (VEGF), thus inhibiting the growth of vasculature. The drug has been used along with chemotherapy in humans to successfully inhibit the growth of tumors in colon and lung cancers.

“If novel drugs can be developed to target tumor heparan sulfate, we might be able to make a leap in cancer-fighting therapies, because several molecules critical to tumor endothelial growth also bind to heparan sulfate,” Fuster said. “Altering this binding would allow for suppression of a broader array of the tumor ‘fuels’ for angiogenesis, without a major effect on normal vascular function.”

The researchers hope to develop novel therapies by inhibiting endothelial heparan sulfate in the tumor environment. An example would be developing small-molecule inhibitors of Ndst1. By affecting a broad array of molecules – such as VEGF, fibroblast growth factor, platelet-derived growth factor, or others that impact angiogenesis in a variety of carcinomas – this therapy could be used to inhibit cancer growth and metastasis with fewer side effects.

Additional contributors to the paper include Lianchun Wang, Janice Castagnola, Krisanavane Reddi, Manuela Shuksz and Joseph R. Bishop, of UCSD’s Department of Cellular and Molecular Medicine, Glycobiology Research and Training Center; Lyudmila Sikora and P. Sriaramarao from the Division of Vascular Biology at the La Jolla Institute for Molecular Medicine; Phillip H.A. Lee, Katherine Radek and Richard L. Gallo, M.D., Ph.D., of the Division of Dermatology, San Diego VA Medical Center and UCSD. The research was funded in part by grants from the National Institutes of Health and the U.S. Department of Veterans Affairs.

 

Tea and Cancer Prevention: Fact Sheet

Key Points


The antioxidants found in tea--called catechins--may selectively inhibit the growth of cancer (see Question 1).

In laboratory studies using animals, catechins scavenged oxidants before cell damage occurred, reduced the number and size of tumors, and inhibited the growth of cancer cells (see Question 3).

However, human studies have proven more contradictory, perhaps due to such factors as variances in diet, environments, and populations (see Question 4).

NCI researchers are investigating the therapeutic and preventive use of tea catechins against a variety of cancers (see Question 5).



Tea drinking is an ancient tradition dating back 5,000 years in China and India. Long regarded in those cultures as an aid to good health, researchers now are studying tea for possible use in the prevention and treatment of a variety of cancers. Investigators are especially interested in the antioxidants-called catechins-found in tea. Despite promising early research in the laboratory, however, studies involving humans so far have been inconclusive.

1. What are antioxidants?

The human body constantly produces unstable molecules called oxidants, also commonly referred to as free radicals. To become stable, oxidants steal electrons from other molecules and, in the process, damage cell proteins and genetic material. This damage may leave the cell vulnerable to cancer. Antioxidants are substances that allow the human body to scavenge and seize oxidants. Like other antioxidants, the catechins found in tea selectively inhibit specific enzyme activities that lead to cancer. They may also target and repair DNA aberrations caused by oxidants (1).

2. What is the level of antioxidants found in tea?

All varieties of tea come from the leaves of a single evergreen plant, Camellia sinensis. All tea leaves are picked, rolled, dried, and heated. With the additional process of allowing the leaves to ferment and oxidize, black tea is produced. Possibly because it is less processed, green tea contains higher levels of antioxidants than black tea.

Although tea is consumed in a variety of ways and varies in its chemical makeup, one study showed steeping either green or black tea for about five minutes released over 80 percent of its catechins. Instant iced tea, on the other hand, contains negligible amounts of catechins (1).

3. What are the laboratory findings?

In the laboratory, studies have shown tea catechins act as powerful inhibitors of cancer growth in several ways: They scavenge oxidants before cell injuries occur, reduce the incidence and size of chemically induced tumors, and inhibit the growth of tumor cells. In studies of liver, skin and stomach cancer, chemically induced tumors were shown to decrease in size in mice that were fed green and black tea (1, 2).

4. What are the results of human studies?

Although tea has long been identified as an antioxidant in the laboratory, study results involving humans have been contradictory. Some epidemiological studies comparing tea drinkers to non-tea drinkers support the claim that drinking tea prevents cancer; others do not. Dietary, environmental, and population differences may account for these inconsistencies.

Two studies in China, where green tea is a mainstay of the diet, resulted in promising findings. One study involving over 18,000 men found tea drinkers were about half as likely to develop stomach or esophageal cancer as men who drank little tea, even after adjusting for smoking and other health and diet factors (3). A second study at the Beijing Dental Hospital found consuming 3 grams of tea a day, or about 2 cups, along with the application of a tea extract reduced the size and proliferation of leukoplakia, a precancerous oral plaque (1).

However, a study in the Netherlands did not support these findings. It investigated the link between black tea consumption and the subsequent risk of stomach, colorectal, lung, and breast cancers among 58,279 men and 62,573 women ages 55 to 69. The study took into account such factors as smoking and overall diet. It found no link between tea consumption and protection against cancer (4).

5. Is NCI evaluating tea?

National Cancer Institute (NCI) researchers are also investigating the therapeutic use of green tea. One recently completed but unpublished NCI trial studied the antitumor effect of green tea among prostate cancer patients. The 42 patients drank 6 grams of green tea, or about 4 cups, daily for four months. However, only one patient experienced a short-lived improvement, and nearly 70 percent of the group experienced unpleasant side effects such as nausea and diarrhea. The study concluded drinking green tea has limited antitumor benefit for prostate cancer patients (5).

Other ongoing NCI studies are testing green tea as a preventive agent against skin cancer. For example, one is investigating the protective effects of a pill form of green tea against sun-induced skin damage while another explores the topical application of green tea in shrinking precancerous skin changes. For more information about NCI-sponsored studies on green tea, go to http://www.cancer.gov/clinical_trials/.

References:
(1) Dufresne CJ, Farnworth ER. A review of latest research findings on the health promotion properties of tea. J. Nutri Biochem 2001; 12 (7): 404-421.
(2) Hakim IA, Harris RB. Joint effects of citrus peel use and black tea intake on risk of squamous cell carcinoma of the skin. BMC Derm 2001; 1 (3).
(3) Sun CL, Yuan JM, Lee MJ, Yang CS, Gao YT, Ross RK, Yu MC. Urinary tea polyphenols in relation to gastric and esophageal cancers: a prospective study of men in shanghai, china. Carcin 2002; 23 (9): 1497-1503.
(4) Goldbohm RA, Hertog MG, Brants HA, van Poppel G, van den Brandt PA. Consumption of black tea and cancer risk: a prospective cohort study. JNCI 1996; 88 2): 93-100.
(5) Phase II Study of Green Tea Extract in Patients with Androgen-Independent Metastic Prostate Cancer. Protocol Ids: NCCTG-N9951. NCI Clinical Trials http://www.cancer.gov/clinical_trials/.

 
Google
Web www.iconocast.com
 
 
Continue News With: News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

 © 2002-2006

Keywords:

Contact Iconocast